JPY 632.0
(-1.25%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 209.13 Million JPY | 446.0% |
2022 | 38.3 Million JPY | 42.52% |
2021 | 26.87 Million JPY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 111 Million JPY | 10.19% |
2024 Q1 | 100.73 Million JPY | -51.83% |
2023 FY | 209.13 Million JPY | 446.0% |
2023 Q4 | 209.13 Million JPY | -15.39% |
2023 Q3 | 247.18 Million JPY | -34.01% |
2023 Q2 | 374.59 Million JPY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
KOHJIN BIO CO LTD | 3.24 Billion JPY | 93.559% |
PRISM BioLab Co.,LTD | 63.41 Million JPY | -229.807% |
GNI Group Ltd. | 26.34 Billion JPY | 99.206% |
Linical Co., Ltd. | 10.3 Billion JPY | 97.971% |
Trans Genic Inc. | 3.81 Billion JPY | 94.515% |
MEDINET Co., Ltd. | 590.2 Million JPY | 64.566% |
Soiken Holdings Inc. | 697.02 Million JPY | 69.996% |
Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 93.077% |
AnGes, Inc. | 2.78 Billion JPY | 92.502% |
OncoTherapy Science, Inc. | 513.6 Million JPY | 59.281% |
Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.769% |
Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 40.801% |
NanoCarrier Co., Ltd. | 1.64 Billion JPY | 87.324% |
Carna Biosciences, Inc. | 472.35 Million JPY | 55.725% |
CanBas Co., Ltd. | 91.98 Million JPY | -127.349% |
D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 80.877% |
RaQualia Pharma Inc. | 809.83 Million JPY | 74.176% |
Chiome Bioscience Inc. | 593.73 Million JPY | 64.776% |
Kidswell Bio Corporation | 4.25 Billion JPY | 95.084% |
PeptiDream Inc. | 29.11 Billion JPY | 99.282% |
Oncolys BioPharma Inc. | 566.5 Million JPY | 63.083% |
Ribomic Inc. | 155.8 Million JPY | -34.225% |
SanBio Company Limited | 2.25 Billion JPY | 90.725% |
Healios K.K. | 11.28 Billion JPY | 98.147% |
BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | 16.769% |
Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 43.324% |
Delta-Fly Pharma, Inc. | 241.49 Million JPY | 13.401% |
StemRIM | 187 Million JPY | -11.836% |
CellSource Co., Ltd. | 677.73 Million JPY | 69.142% |
FunPep Company Limited | 189.32 Million JPY | -10.464% |
Kringle Pharma, Inc. | 596.95 Million JPY | 64.967% |
Stella Pharma Corporation | 1.44 Billion JPY | 85.513% |
TMS Co., Ltd. | 97.68 Million JPY | -114.081% |
Noile-Immune Biotech Inc. | 91.49 Million JPY | -128.577% |
Cuorips Inc. | 200.96 Million JPY | -4.067% |
Takara Bio Inc. | 11.42 Billion JPY | 98.169% |
ReproCELL Incorporated | 741.03 Million JPY | 71.778% |
PhoenixBio Co., Ltd. | 917.71 Million JPY | 77.211% |
StemCell Institute Inc. | 3.85 Billion JPY | 94.569% |
Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 76.979% |
CellSeed Inc. | 301.04 Million JPY | 30.531% |